Bereich
Dermatologie | Venerologie | Allergologie
DERMA · Dept. IV
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
19.02.2012The study is a global Phase III, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the safety and efficacy of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and ad...
Klinische Forschung - 19.02.2012 - 19.06.2013
Automatisch geschlossen
Projektleitung: Anliker Mark
Swiss Dermatology Network for Targeted Therapies (SDNTT) Objective Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg
31.01.2012
Klinische Forschung - 31.01.2012 - 31.12.2030
Laufend
Projektleitung: Cozzio Antonio
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
15.11.2011Purpose: To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
Klinische Forschung - 15.11.2011 - 01.12.2013
Automatisch geschlossen
Projektleitung: Anliker Mark
A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
15.11.2011The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the q...
Klinische Forschung - 15.11.2011 - 19.04.2015
Automatisch geschlossen
Projektleitung: Anliker Mark
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
19.10.2011This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
Klinische Forschung - 19.10.2011 - 19.09.2012
Automatisch geschlossen
Projektleitung: Anliker Mark
Registerstudie CARPE-CH chronisches Handekzem
19.07.2011Mit dieser Studie sollen wichtige und bisher fehlende Daten zu chronischen Handekzemen strukturiert erhoben werden, durch die neue Erkenntnisse zur Ursache, Therapie und Prognose von Handekzemen zu erwarten sind. Insbesondere sollen dadurch Erkenntni...
Klinische Forschung - 19.07.2011 - 19.07.2013
Automatisch geschlossen
Projektleitung: Anliker Mark
A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma; Short Title: GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy iin patients with resexted melanoma
22.12.2010A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma; Short Title: GSK 2132231A Antigen-Specific Cancer Immun...
Grundlagenforschung - 22.12.2010 - 31.12.2015
Automatisch geschlossen
Projektleitung: Heinzerling Lucie
clinical study; The tolerance of acid textiles (pH 5.5-6.5) in patients with atopic and/or dry skin - a randomized, double blind, placebo-controlled study conducted by Kantonsspital St. Gallen
22.12.2010clinical study; The tolerance of acid textiles (pH 5.5-6.5) in patients with atopic and/or dry skin - a randomized, double blind, placebo-controlled study conducted by Kantonsspital St. Gallen
Klinische Forschung - 22.12.2010 - 22.12.2010
Abgeschlossen
Projektleitung: Heinzerling Lucie
Assessment of a novel lyophilizable virosome formulation as an adjuvant to the induction of effector cells specific for Melan-A/MART-1 melanoma associated antigen
01.02.2010Die Zahl der Melanompatienten nimmt kontinuierlich zu. Wirksame Therapieansätze nach der chirurgischen Entfernung des Tumors fehlen leider. Chemotherapie und Strahlentherapie sind nur bedingt wirksam. Längst wurde erkannt, dass das menschliche Abwehr...
Grundlagenforschung - 01.02.2010 - 31.01.2011
Abgeschlossen
Projektleitung: Adamina Michel
Mitarbeiter/innen: Heinzerling Lucie, Weder Patrik
A Phase II, randomized, double-blind, placebo
07.12.2009A Phase II, randomized, double-blind, placebo -controlled, multi-centre study of the savety and efficacy of CT 327, Pegylated K-252, formulated as a cream, when administered twice daily for 14 days to subjects with Mild-to-Moderate atopic Dermatit...
Klinische Forschung - 07.12.2009 - 30.10.2010
Abgeschlossen
Projektleitung: Heinzerling Lucie
A randomized, double-blind, placebo controlled Phase
07.12.2009A randomized, double-blind, placebo controlled Phase II, multi-centre study of the efficacy and safety of CT 327, a topical cream formulation of Pegylated K252a, when administered twice daily for eight weeks to patients with mild to moderate Ps...
Klinische Forschung - 07.12.2009 - 25.11.2010
Abgeschlossen
Projektleitung: Heinzerling Lucie